Zobrazeno 1 - 8
of 8
pro vyhledávání: '"Andrew Welland"'
Autor:
Archie Macnair, Matthew Nankivell, Macey L. Murray, Stuart D. Rosen, Sally Appleyard, Matthew R. Sydes, Sylvia Forcat, Andrew Welland, Noel W. Clarke, Stephen Mangar, Howard Kynaston, Roger Kockelbergh, Abdulla Al-Hasso, John Deighan, John Marshall, Mahesh Parmar, Ruth E. Langley, Duncan C. Gilbert
Publikováno v:
Contemporary Clinical Trials. 128:107162
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::7513bab1f6318c96696440513903c9ba
https://doi.org/10.1016/j.cct.2023.107162
https://doi.org/10.1016/j.cct.2023.107162
Autor:
Richard J. Wassersug, Andrew Welland, Duncan C. Gilbert, Stuart D. Rosen, Trinh Duong, Mahesh K. B. Parmar, Alvan Pope, Sanjeev Madaan, Gerald N. Collins, Paul D. Abel, Ruth E Langley, Abdulla Alhasso, M. Laniado, Matthew Nankivell, Sanjay Dixit, Howard Kynaston, Fay H. Cafferty, Subramanian Kanaga-Sundaram
Objectives\ud \ud To compare quality-of-life (QoL) outcomes at 6 months between men with advanced prostate cancer receiving either transdermal oestradiol (tE2) or luteinising hormone-releasing hormone agonists (LHRHa) for androgen-deprivation therapy
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3804d1b47b00be95332b40b4068e15db
https://orca.cardiff.ac.uk/id/eprint/102641/1/Gilbert_et_al-2017-BJU_International.pdf
https://orca.cardiff.ac.uk/id/eprint/102641/1/Gilbert_et_al-2017-BJU_International.pdf
Autor:
Ruth E, Langley, Howard G, Kynaston, Abdulla A, Alhasso, Trinh, Duong, Edgar M, Paez, Gordana, Jovic, Christopher D, Scrase, Andrew, Robertson, Fay, Cafferty, Andrew, Welland, Robin, Carpenter, Lesley, Honeyfield, Richard L, Abel, Michael, Stone, Mahesh K B, Parmar, Paul D, Abel
Publikováno v:
European urology. 69(6)
Luteinising hormone-releasing hormone agonists (LHRHa), used as androgen deprivation therapy (ADT) in prostate cancer (PCa) management, reduce serum oestradiol as well as testosterone, causing bone mineral density (BMD) loss. Transdermal oestradiol i
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::ee3cec6977c0d9fec15bc5f5f4488ef7
https://pubmed.ncbi.nlm.nih.gov/26749094
https://pubmed.ncbi.nlm.nih.gov/26749094
Autor:
Stuart D. Rosen, Howard Kynaston, Noel W. Clarke, Trinh Duong, Anna Bara, Abdulla Alhasso, Ruth E Langley, David P. Dearnaley, Andrew Welland, Paul D. Abel, Roger Kockelbergh, Ian F. Godsland, Mahesh K. B. Parmar, Gordana Jovic, Robin Carpenter
Publikováno v:
Maturitas. 81:210-211
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::c182a8ebd6c5c181409f2fd9f2733751
https://doi.org/10.1016/j.maturitas.2015.02.320
https://doi.org/10.1016/j.maturitas.2015.02.320
Autor:
Andrew, Welland, Simon, Daff
Publikováno v:
The FEBS journal. 277(18)
Calmodulin (CaM) activates the constitutive isoforms of mammalian nitric oxide synthase by triggering electron transfer from the reductase domain FMN to the heme. This enables the enzymes to be regulated by Ca(2+) concentration. CaM exerts most of it
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::04280174c9dad1316e265336389ebd10
https://pubmed.ncbi.nlm.nih.gov/20718865
https://pubmed.ncbi.nlm.nih.gov/20718865
Autor:
Alastair W. S. Ritchie, Tim Eisen, Andrew Welland, Louise Choo, Ben Smith, Adam Gregory, Angela M. Meade, Richard Kaplan
Publikováno v:
Journal of Clinical Oncology. 32:496-496
496 Background: SORCE is a randomised double blind trial of sorafenib, given for one or three years, versus placebo for patients at moderate or high risk of disease recurrence after surgical excision of primary renal cell carcinoma (RCC). Methods: Be
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::d19789be2c5b3528abc7cbb29ffa5fb0
https://doi.org/10.1200/jco.2014.32.4_suppl.496
https://doi.org/10.1200/jco.2014.32.4_suppl.496
Autor:
Andrew Welland, Simon Daff
Publikováno v:
FEBS Journal. 277:3833-3834
Calmodulin (CaM) activates the constitutive isoforms of mammalian nitric oxide synthase by triggering electron transfer from the reductase domain FMN to the heme. This enables the enzymes to be regulated by Ca2+ concentration. CaM exerts most of its
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::265ec8a016c081c861cb24f931b7c3a9
https://doi.org/10.1111/j.1742-4658.2010.07787.x
https://doi.org/10.1111/j.1742-4658.2010.07787.x
Publikováno v:
Welland, A, Garnaud, P E, Kitamura, M, Miles, C S & Daff, S 2008, ' Importance of the domain-domain interface to the catalytic action of the NO synthase reductase domain ', Biochemistry, vol. 47, no. 37, pp. 9771-9780 . https://doi.org/10.1021/bi800787m
Calmodulin (CaM) activates NO synthase (NOS) by binding to a 20 amino acid interdomain hinge in the presence of Ca2+, inducing electrons to be transferred from the FAD to the heme of the enzyme via a mobile FMN domain. The activation process is influ
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9f232c969763f227b58a0a1d5e9d6551
https://doi.org/10.1021/bi800787m
https://doi.org/10.1021/bi800787m